Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
SAN FRANCISCO and SUZHOU, China, May 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of a Phase 3 clinical study of mazdutide , a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with overweight or obesity (GLORY-1) have been published in The New England Journal of Medicine (NEJM) with a related editorial [https://www.nejm.org/doi/full/10.1056/NEJMoa2411528]. The first authors of this paper are Professor Linong Ji from Peking University People's Hospital and Professor Jiang Hongwei from the First Affiliated Hospital of Henan University of Science and Technology. In addition, Professor Linong Ji and Dr. Lei Qian from Innovent Biologics, served as the co-corresponding authors.
This marks the first time that a clinical study of mazdutide, the world's first dual GCG/GLP-1 receptor agonist submitted for marketing, has been featured in a top-tier, peer-reviewed medical journal. It is also the first time a clinical trial of an innovative metabolic and endocrine therapy developed in China has been published in NEJM, a milestone that highlights China's growing capabilities in drug development and biotechnology innovation. This publication is expected to contribute to the evolving global clinical guidelines for the treatment of overweight and obesity.
Regarding this groundbreaking new study, Professors Vanita R. Aroda of Harvard Medical School and Brigham and Women's Hospital, Boston, and Leigh Perreault of the University of Colorado Anschutz Medical Campus jointly commented that the GLORY-1 trial reveals distinct characteristics in the Chinese population compared to Western populations. Specifically, younger individuals in China exhibit metabolic dysfunction at rates comparable to or even exceeding those in older Western populations. The dual GCG/GLP-1 receptor agonist therapy demonstrated not only significant reductions in body weight and BMI but also comprehensive improvements in obesity-associated systemic health risks. Moreover, they emphasized that obesity interventions in China must adopt differentiated strategies tailored to local population features, with a focus on liver health and lipid management. Given the earlier onset of obesity in China and its heavier societal burden, earlier intervention is critical—and yields greater long-term benefits. For emerging obesity therapies, the experts noted that pharmacological treatments are only one component of a broader strategy. They advocated for synergizing drug therapies with public health policies to build a comprehensive prevention and treatment system, addressing the global obesity epidemic more effectively.
Mazdutide is expected to launch in China this year, with anticipated approvals for weight management and glycemic control. Recognized for its superior weight loss efficacy and comprehensive metabolic benefits, mazdutide has been ranked among FIERCE Pharma's 2025 Top 10 Most Anticipated Drugs.
In the GLORY-1 study, a total of 610 participants with obesity (BMI ≥ 28 kg/m2) or overweight (24 kg/m2 ≤ BMI < 28 kg/m2) with at least one obesity-related comorbidity were enrolled and randomized to receive mazdutide 4 mg, 6 mg, or placebo, administered subcutaneously once weekly for 48 weeks. The co-primary endpoints were the percentage change in body weight from baseline and a weight reduction of ≥5% at week 32.
At baseline, the mean weight was 87.2 kg, and the mean BMI was 31.1 kg/m 2. The study results showed that mazdutide significantly reduced body weight compared to placebo at both 4 mg and 6 mg doses.
Based on the efficacy estimand, the mean percent change from baseline in body weight was −10.97%, −13.38%, and −0.24% at Week 32 and −12.05%, −14.84%, and −0.47% at Week 48 in the mazdutide 4 mg, 6 mg, and placebo groups, respectively. A total of 76.3% of participants in the mazdutide 4 mg group and 84.0% in the mazdutide 6 mg group had a weight reduction of ≥5% at week 32, compared with 10.9% in the placebo group; 37.0% of participants in the mazdutide 4 mg group and 50.6% in the mazdutide 6 mg group had a weight reduction of ≥15% at week 48, compared with 2.1% in the placebo group.
The primary endpoint and all key secondary endpoints of the study showed statistically significant superiority to placebo with p-values < 0.001 (main results as follows).Efficacy Estimand1
Treatment-policy estimand2Mazdutide
4 mg (N=203)
Mazdutide
6 mg (N=202)
Placebo
(N = 205)
Mazdutide
4 mg (N=203)
Mazdutide
6 mg (N=202)
Placebo
(N = 205)
Co-primary endpoints (Week 32)
Percent weight reduction
−10.97%
−13.38%
−0.24%
−10.09%
−12.55%
0.45 %
Achieved a weight reduction ≥5%
76.3 %
84.0 %
10.9 %
73.9 %
82.0 %
10.5 %
Some key secondary endpoints (Week 48)
Percent weight reduction
−12.05%
−14.84%
−0.47%
−11.00%
−14.01%
0.30 %
Achieved a weight reduction ≥5%
73.5 %
82.8 %
11.5 %
71.6 %
81.6 %
10.8 %
Achieved a weight reduction ≥10%
55.2 %
67.9 %
2.9 %
53.5 %
66.7 %
2.6 %
Achieved a weight reduction ≥15%
37.0 %
50.6 %
2.1 %
35.7 %
49.5 %
2.0 %
Waist circumference reduction
−9.48 cm
−10.96 cm
−1.48 cm
−9.12 cm
−10.72 cm
−1.41 cm
1. Efficacy estimand aims to estimate the study treatment effect when participants adhered to the planned treatment regimen.
2. Treatment policy estimand aims to evaluate the efficacy regardless of intercurrent events (early discontinuation of study treatment and initiation of new anti-obesity medication or bariatric surgery).
Mazdutide also significantly reduced blood pressure, blood lipids (total cholesterol, triglycerides, and low-density lipoprotein cholesterol), serum uric acid, transaminase levels, and other cardiovascular and metabolic indicators.
In addition, mazdutide significantly reduced liver fat content.
Among participants with baseline liver fat content ≥ 5%, the mean percent changes in liver fat content from baseline to week 48 were −63.26%, −73.18%, and +8.20% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively;
Among participants with baseline liver fat content ≥ 10%, the mean percent change from baseline in liver fat content to week 48 were −65.85%, −80.24%, and −5.27% in the mazdutide 4 mg, 6 mg, and placebo groups, respectively.
Good overall safety and tolerability of mazdutide were reported.
The overall safety profile of the mazdutide group was consistent with findings from previous studies of mazdutide and aligned with that of other GLP-1 receptor agonists. The most frequently reported treatment-emergent adverse events included nausea, diarrhea, and vomiting, which were mostly mild or moderate in severity.
At Week 48, both the mean change from baseline in heart rate was 2.6 beats per minute in both the mazdutide 4 mg and 6 mg groups. There were no safety signals of increased cardiovascular risk observed throughout the study.
Professor Linong Ji, the Leading Principal Investigator of the Study, Peking University People's Hospital, stated, "For decades, global obesity management guidelines have predominantly relied on data from Caucasian populations, resulting in limited applicability to Asian demographics. Meanwhile, China's overweight/obese population exhibits distinct clinical characteristics and therapeutic needs compared to Western populations, necessitating evidence-based weight management strategies specifically tailored for Chinese patients. For most Chinese patients with overweight or obesity, the recommended weight loss target should be 5%-15% reduction maintained over 3-6 months. Moderate-to-severe obesity patients may require more ambitious goals. The GLORY-1 study, conducted in Chinese populations aligned with these targets, demonstrated promising outcomes: mazdutide achieved >15% weight reduction in nearly half of participants, indicating its efficacy across people living with overweight to severe obesity.
Published in The New England Journal of Medicine, the GLORY-1 study not only signifies international recognition of China's innovative research in endocrine-metabolic disorders but also underscores the pioneering innovation of Chinese biopharmaceutical industry. Mazdutide's successful development will accelerate domestic enterprises' strategic presence in obesity management, enabling comprehensive, personalized solutions for China's overweight/obese population throughout their treatment journey."
Dr. Lei Qian from Innovent Biologics, stated, "Mazdutide is globally first dual GCG/GLP-1 receptor agonist to be approved soon. The publication of its pivotal study GLORY-1 in The New England Journal of Medicine marks a breakthrough in China's drug development in endocrine and metabolic diseases. The study provides robust, high-quality clinical evidence for treating overweight and obesity in Chinese adults and will undoubtedly influence future clinical guidelines, diagnostic criteria, and standards of care. This academic achievement also demonstrates the exceptional clinical research capabilities of Chinese investigators and the solid innovative R&D abilities of Innovent. With mazdutide's imminent approval in China, we look forward to offering an advanced therapeutic option to improve the health and quality of life of individuals living with overweight or obesity. As an innovative pharmaceutical company, Innovent has actively responded to and promoted the goal of 'Healthy China 2030' by advancing science-based weight management through strategic collaborations and cutting-edge medical achievements. "
About Obesity
China has the world's largest population of individuals with overweight or obesity[1], a trend that is likely to rise. Obesity is associated to multiple comorbidities, and is a major contributor to reduced life expectancy and quality of life. In 2019, overweight and obesity accounted for 11.1% of deaths from chronic non-communicable diseases in China, nearly doubling from 5.7% in 1990[2].
Despite the chronic nature of obesity and its need for long-term management, treatment options remain limited. While lifestyle interventions remains the cornerstone of treatment, many patients struggle to achieve or maintain meaningful weight reduction. This underscores the urgent need for safe, effective and sustainable pharmacological interventions.
About Mazdutide (IBI362)
Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity.
Mazdutide currently has two NDAs accepted for review by NMPA, including:
For chronic weight management in adults with overweight or obesity;
For glycemia control in adults with type 2 diabetes.
Mazdutide is currently being evaluated in six Phase 3 clinical studies, including:
GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity.
GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity.
GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD).
DREAMS-1: A Phase 3 trial in treatment-naïve Chinese patients with T2D.
DREAMS-2: A Phase 3 trial comparing mazdutide and dulaglutide in Chinese T2D patients with inadequate glycemic control on oral antidiabetic drugs.
DREAMS-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese patients with T2D and obesity.
Among these, GLORY-1, DREAMS-1 and DREAMS-2 studies have all met their endpoints, and other studies are currently ongoing.
In addition, several new clinical studies of mazdutide are planned, including:
A Phase 3 trial in adolescents with obesity.
A Phase 3 trial in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity.
New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF).
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.
Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Statement: (1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).
(2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.
Forward-looking statement
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
References
[1] Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 2021; 9: 373–92.
[2] Institute for Health Metrics and Evaluation. Global Health Data Exchange. GBD results tool. http://ghdx.healthdata.org/gbd-resultstool (accessed Jan 10, 2021).
View original content:https://www.prnewswire.com/apac/news-releases/phase-3-clinical-study-of-mazdutide-in-chinese-adults-with-overweight-or-obesity-glory-1-published-in-the-new-england-journal-of-medicine-nejm-302464872.html
SOURCE Innovent Biologics
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
One Weight Loss Strategy Is 5x More Effective Than Ozempic, Trials Show
Ozempic and other semaglutide medications have been working wonders in terms of shedding pounds for many people, but a new study shows that they're still not as effective as surgery when it comes to weight loss – and it's not even close. Researchers from New York University (NYU) compared sleeve gastrectomy and gastric bypass operations against semaglutide or tirzepatide. These drugs are known as glucagon-like peptide-1 (GLP-1) receptor agonists, because of the way they mimic the natural GLP-1 hormone, which controls appetite. Using health records, the team matched people who had taken one of the weight loss drugs with people who had undergone either of the bariatric surgery operations, based on age, body mass index, and blood sugar levels. The bottom line: people in the surgery group shed an average of 25.7 percent of their total body weight over two years, while those in the medication group lost 5.3 percent. That's partly down to patients not sticking to their GLP-1 drugs, whereas surgery is more permanent, but the researchers also noticed smaller differences over shorter time frames – the surgery always gave the best results. "Clinical trials show weight loss between 15 percent to 21 percent for GLP-1s, but this study suggests that weight loss in the real world is considerably lower even for patients who have active prescriptions for an entire year," says Avery Brown, a surgical resident at NYU Langone Health. "We know as many as 70 percent of patients may discontinue treatment within one year. GLP-1 patients may need to adjust their expectations, adhere more closely to treatment or opt for metabolic and bariatric surgery to achieve desired results." It's worth noting, however, that the study was funded by the American Society for Metabolic and Bariatric Surgery (ASMBS), who would have a vested interest in promoting surgical options. That said, the researchers aren't outright dismissing semaglutide treatments, which also showed beneficial results in this study. With GLP-1 prescriptions doubling from 2022 to 2023, it's crucial to investigate how they compare to established surgery methods, and to figure out which options are best for each individual. GLP-1 drugs remain much more popular than surgery, but people don't often stick to taking them. Meanwhile, only a small percentage of people eligible for surgery choose it as an option. Weight loss isn't the only benefit that can come from Ozempic. The drug was originally approved as a way to treat type 2 diabetes, because it helps lower blood sugar levels, and studies have shown it can also reduce the risk of cancer and cardiovascular disease. In this study, bariatric surgery was associated with even better blood sugar control. It's also important to note that surgery isn't a silver bullet either. Though safe, the procedures are invasive, permanent, and still require patients to stick to strict diet and exercise routines. "In future studies we will aim to identify what healthcare providers can do to optimize GLP-1 outcomes, identify which patients are better treated with bariatric surgery versus GLP-1s, and determine the role out-of-pocket costs play in treatment success," says Karan Chhabra, a bariatric surgeon at the NYU Grossman School of Medicine. The research was presented at the ASMBS annual meeting 2025. There's a Shocking Reason Ticks Are So Dangerous (It's Us) Cannabis Linked to 2x Risk of Heart Disease Death, Scientists Discover 5 Daily Habits Could Be Causing Your Liver Serious Harm
Yahoo
an hour ago
- Yahoo
The Sad Case of The World's Youngest-Ever Alzheimer's Diagnosis
In 2023, neurologists at a memory clinic in China diagnosed a 19-year-old with what they believed to be Alzheimer's disease – making him the youngest person ever to be diagnosed with the condition. The teen first began experiencing memory decline around age 17, with symptoms worsening over time. Brain scans revealed shrinkage in the hippocampus, a region involved in memory, while his cerebrospinal fluid showed biomarkers consistent with Alzheimer's – the most common form of dementia. Although usually associated with older age, early-onset cases of Alzheimer's (those occurring in individuals under age 65) represent up to 10 percent of all diagnoses. Almost all Alzheimer's patients under the age of 30 can have their disease explained by pathological gene mutations, classifying them as having familial Alzheimer's disease (FAD). The younger a person is when they receive a diagnosis, the more likely it is caused by an inherited faulty gene. However, researchers at Beijing's Capital Medical University were unable to find any of the usual mutations responsible for the early onset of memory loss, nor any suspect genes, after conducting a genome-wide search. Before this diagnosis in China, the youngest patient with Alzheimer's was 21 years old. They carried the PSEN1 gene mutation, which causes abnormal proteins to build up in the brain, forming clumps of toxic plaques, a common feature of Alzheimer's. Cases like this one pose something of a mystery. None of the 19-year-old's family had a history of Alzheimer's or dementia, making it hard to categorize it as FAD, yet the teenager had no other diseases, infections, or head trauma that could explain his sudden cognitive decline either. Two years before being referred to the memory clinic, the teenage patient began struggling to focus in class. Reading also became difficult and his short-term memory declined. Oftentimes, he couldn't remember events from the day before, and he was always misplacing his belongings. Ultimately, the cognitive decline became so bad, the young man was unable to finish high school, although he could still live independently. A year after being referred to the memory clinic, he showed losses in immediate recall, short-delay recall after three minutes, and long-delay recall after 30 minutes. The patient's full-scale memory score was 82 percent lower than that of peers his own age, while his immediate memory score was 87 percent lower. Long-term follow-up is needed to support the young man's diagnosis, but his medical team said at the time the patient was "altering our understanding of the typical age of onset of AD." "The patient had very early-onset AD with no clear pathogenic mutations," neurologist Jianping Jia and colleagues wrote in their study, "which suggests that its pathogenesis still needs to be explored." The case study, published in February 2023, just goes to show that Alzheimer's doesn't follow a single pathway, and is much more complex than we thought, emerging via numerous avenues with varying effects. In a statement to the South China Morning Post, the neurologists who described the patient's case argued that future studies should focus on early-onset cases to further improve our understanding of memory loss. "Exploring the mysteries of young people with Alzheimer's disease may become one of the most challenging scientific questions of the future," they said. The study was published in the Journal of Alzheimer's Disease. An earlier version of this article was published in February 2023. Compound That Turns People Yellow Could Protect Against Malaria Scientists May Have Finally Figured Out How Bats Avoid Cancer 'Off Switch' in The Brain to Stop Binge Drinking Discovered in Mice
Associated Press
an hour ago
- Associated Press
Key Findings from the "Hong Kong Vitiligo Patients and Caregivers Survey" Released for "World Vitiligo Day"
Patients Demonstrate Significant Knowledge Gaps in Treatment Options, Leading to Lost Hope and Treatment Discontinuation Over 70% of Vitiligo Patients Desire Skin Repigmentation; New Topical Therapy Introduced in Hong Kong Shows Encouraging Results HONG KONG SAR - Media OutReach Newswire - 22 June 2025 - In observance of World Vitiligo Day (June 25), Hong Kong Vitiligo Support Group has released findings from its latest 'Hong Kong Vitiligo Patients and Caregivers Survey.' The study reveals critical gaps in treatment knowledge, with over 80% of respondents demonstrating limited understanding of available therapies and their efficacy. More than 70% of patients hoped therapy could partially or fully restore their original skin pigmentation, yet many reported disappointing outcomes with existing treatments, leading to loss of confidence and treatment discontinuation. (From left) Mr. Chan (pseudonym), a patient with vitiligo; Dr. Chan Yung, a specialist in dermatology; and Ms. Amy Wong, a registered social worker from the Hong Kong Vitiligo Support Group, urge individuals with vitiligo to seek professional medical consultation for personalized treatment plan promptly and to avoid unproven remedies Dr. Chan Yung, a specialist in dermatology, noted that with advancing insights into vitiligo pathogenesis, novel therapy has recently been introduced in Hong Kong. Clinical studies confirm its repigmentation potential, encouraging patients to consult specialists for personalized treatment plans. In Hong Kong, vitiligo affects approximately 1% of the population, with an estimated 70,000 individuals living with the condition. In May 2025, Hong Kong Vitiligo Support Group successfully surveyed 61 patients or their primary caregivers to identify key challenges in disease management. Key findings as follows: 1. Critical Knowledge Deficits in Treatment Understanding 2. Disparity Between Treatment Expectations and Outcomes 3. Treatment Discontinuation Due to Lost Confidence Vitiligo is classified as segmental (SV) or non-segmental (NSV), with 90% of cases being NSV—a subtype with higher progression risk and greater therapeutic difficulty. Traditional options (e.g., topical corticosteroids, topical calcineurin inhibitors, phototherapy) often yield variable results, with limitations such as: Over 70% of Vitiligo Patients Seek Skin Repigmentation - New Topical Treatment Introduced in Hong Kong Offers Hope Dr. Chan Yung stated that targeted therapies like topical JAK inhibitors represent a breakthrough in vitiligo treatment. 'Topical JAK inhibitors are non-steroidal medications with demonstrated efficacy and safety profiles, making them a viable long-term treatment option for patients,' he explained. While the exact etiology of vitiligo remains unclear, current evidence suggests autoimmune-mediated attack on melanocytes plays a key pathogenic role, resulting in depigmented lesions. Non-steroidal Topical JAK inhibitors work by modulating the aberrant immune signaling responsible for melanocyte attack, enabling gradual repigmentation of affected areas. Ruxolitinib cream, the first FDA-approved non-steroidal topical JAK inhibitor for localized treatment of non-segmental vitiligo in patients aged 12 years and above, has recently become available in Hong Kong. Clinical trials show: Ms. Amy Wong, a Registered Social Worker at Hong Kong Vitiligo Support Group noted that many vitiligo patients and caregivers seeking assistance express confusion about treatment options and medication efficacy. 'Many patients spend over a year just obtaining a definitive diagnosis,' she explained. 'In their search for solutions, patients often invest substantial resources in various cosmetic packages and alternative therapies, only to experience significant discrepancies between desired and actual outcomes. This frequently leads to disillusionment, loss of hope for effective treatment, and even emotional distress.' 'However,' Ms. Wong emphasized, 'with medical advancements, vitiligo is no longer considered untreatable. Repigmentation is now achievable, and we strongly encourage patients to seek professional medical consultation at the earliest opportunity.' Conclusion and Recommendations The survey reveals significant gaps in patients' understanding of vitiligo treatments and their mechanisms, leaving many uncertain about where to begin treatment. Over 80% of respondents expressed desire for patient support in medication access and resource referrals. Accordingly, Dr. Chan Yung and Ms. Amy Wong, propose the following recommendations: 1. Public Education Seminars Conduct lectures and workshops to help patients and caregivers understand that vitiligo requires long-term management, with visible results often taking extended periods to manifest. These initiatives should also educate participants about various treatment modalities, particularly newly available options like non-steroidal topical JAK inhibitors, enabling informed discussions with healthcare providers about appropriate treatment plans. 2. Medication Support and Resource Referral Services Given that vitiligo necessitates prolonged treatment, and considering that many patients find private care cost-prohibitive while public service wait times are excessively long, we recommend establishing medication support and resource referral services to facilitate timely access to proper treatment. Hong Kong Vitiligo Support Group is currently implementing a 'Vitiligo Patient Support Program,' offering free psychological counseling, medication assistance, and resource referral services. Interested individuals may contact Hong Kong Vitiligo Support Group for details. Case Study Mr. Chan (pseudonym), 58, first developed symptoms thirty years ago with a small depigmented spot on his neck that subsequently spread to his neck, waist, wrists, and thighs. At diagnosis, his physician prescribed topical corticosteroids but stated vitiligo was essentially 'incurable.' Mr. Chan subsequently pursued numerous alternative treatments including UV light therapy, traditional Chinese medicine, electroacupuncture, topical shampoo applications, and cosmetic packages - exhausting savings and liquidating his stocks - all without achieving satisfactory repigmentation. After years of unsuccessful treatment attempts, he discontinued treatment until being referred to the Hong Kong Vitiligo Support Group. Through their seminars and 'Vitiligo Patient Support Program', he learned about modern treatment advances and, with medication assistance, has begun new therapy with renewed hope for repigmentation. 'My greatest wish is to wear crew-neck shirts again,' Mr. Chan shared. 'Since developing vitiligo, I've only worn high-collared shirts to conceal neck patches and haven't gone swimming in thirty years.' He looks forward to regaining sartorial freedom following successful repigmentation. Hashtag: #Vitiligo #WorldVitiligoDay #TopicalJAKinhibitors #Non-steroidalTopicalJAKinhibitors #Ruxolitinibcream #SkinRepigmentation # #Dermatology #Skincare#HongKongVitiligoSupportGroup The issuer is solely responsible for the content of this announcement. About Hong Kong Vitiligo Support Group Initiated by social enterprise Hong Kong Health Care Alliance, Hong Kong Vitiligo Support Group is a non-profit patient organization dedicated to individuals affected by vitiligo and their caregivers. Our mission is to enhance societal understanding of vitiligo through comprehensive disease education and support services, empowering patients to better understand and confront their condition while fostering public awareness. We strive to ensure no patient faces this journey alone.
